Diagonal Bio announces successful external validation of LAMPlify® for viruses in pigs
Diagonal Bio AB (publ) (“Diagonal” or “the Company”) announces successful results of a recent pilot study conducted by the Centre for Diagnostics at DTU Health Technology. The study evaluated the performance of the LAMPlify® assay panel for tests specific to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) type 1 and type 2, and Swine Influenza Virus (SIV), by comparing it to the gold-standard PCR (qPCR) tests.
The study showed excellent agreement between the LAMPlify® assays and qPCR tests, yielding identical positive/negative classifications between the methods. The samples were selected by Centre for Diagnostics, DTU (Danmarks Tekniske Universitet), among the ones submitted for diagnostic examination at the Veterinary Institute. In total, four PRRSV1 positive, one PRRSV2 positive and eight SIV positive samples were included in this study.
“This specificity of the LAMPlify® assays is crucial for accurate diagnostics, ensuring their reliability in various testing scenarios. The pilot study demonstrated high specificity, with no cross-reactivity observed with non-target samples or the negative control. Each assay reliably detected its respective target virus—PRRSV1, PRRSV2, or SIV—without generating false positive results from other samples.”
“Furthermore, at the Centre for Diagnostics, we have found the LAMPlify® platform to be highly user-friendly. The ease of use, combined with the robust performance of the assays, makes LAMPlify® an excellent choice for laboratories seeking reliable and efficient diagnostic tools,” - Helene Larsen Head of Centre for Diagnostics at DTU Health Tech.
Helene Larsen highlighted the LAMPlify® platform’s intuitive design and straightforward protocol, which facilitate seamless integration into existing workflows. This minimizes training time and reduces the potential for user error. Overall, the LAMPlify® assays provide a dependable and practical solution for detecting PRRSV1, PRRSV2, and SIV, supporting both research and clinical applications with high accuracy and ease of use.
“Diagonal Bio has once again demonstrated impressive results and this time in a different market segment of swine diseases. These results reinforce our confidence in the strength and reliability of our platform. Testing is extremely important to breeders to avoid adverse effects on production and minimize economic losses. I am incredibly proud of the new results and look forward to our continued journey in animal welfare,” – Karin Wehlin, CEO Diagonal Bio AB (publ)
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 11, 2024, at 14:30 CET.
For more information, please contact:
Karin Wehlin, CEO
Phone: +46 (0)70305 24 88
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.